Barclays Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1065
REGNNovember 1, 2024
Read more →BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1190
REGNNovember 1, 2024
Read more →Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $1126
REGNNovember 1, 2024
Read more →Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1195
REGNNovember 1, 2024
Read more →Regeneron Sees FY24 Non-GAAP Gross Margin On Net Product Sales Approximately 89%, Unchanged From Prior
REGNOctober 31, 2024
Read more →Regeneron Pharmaceuticals Q3 2024 Adj. EPS $12.46 Beats $11.69 Estimate, Sales $3.720B Beat $3.670B Estimate
REGNOctober 31, 2024
Read more →(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
REGNMay 20, 2024
Read more →Regeneron Pharmaceuticals And Sanofi Present Late-Breaking Data From NOTUS Confirmatory Phase 3 COPD Trial Of Use Of Dupixent; Presented At ATS And Published In New England Journal of Medicine
REGNMay 20, 2024
Read more →Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
REGNMay 17, 2024
Read more →Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $775
REGNSeptember 13, 2022
Read more →Wells Fargo Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $800
REGNSeptember 12, 2022
Read more →Regeneron's Bispecific Antibodies Show Encouraging Anti Tumor Activity
REGNSeptember 12, 2022
Read more →Regeneron Pharmaceuticals Announced 63% Combined Pathologic Response Rate for Neoadjuvant Libtayo Monotherapy in Stage II to IV Resectable CSCC Per Primary Analysis of a Confirmatory Phase 2 Trial; Data Presented at ESMO
REGNSeptember 12, 2022
Read more →9 Analysts Have This to Say About Regeneron Pharmaceuticals
REGNAnalysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:
September 9, 2022
Read more →Analyst Ratings for Regeneron Pharmaceuticals
REGNWithin the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings:
September 9, 2022
Read more →Jefferies Upgrades Regeneron Pharmaceuticals: Here's What You Need To Know
REGNJefferies upgraded its rating of Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold with a price target of $675.00, changing its price target from $536.00 to $675.00. Shares of Regeneron Pharmaceuticals are trading up 4.39% over the last 24 hours, at $739.99 per share.
September 9, 2022
Read more →'Highly Compelling' Eye Drug Data Has Wall Street Stampeding To Buy This 'Large Cap Growth Story.' Even After $15B In Market Cap Was Added
REGNSeptember 9, 2022
Read more →What 9 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
REGNOver the past 3 months, 9 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
September 9, 2022
Read more →Barclays Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $815
REGNSeptember 9, 2022
Read more →Morgan Stanley Upgrades Regeneron Pharmaceuticals to Overweight, Raises Price Target to $851
REGNSeptember 9, 2022
Read more →SVB Leerink Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $756
REGNSeptember 9, 2022
Read more →Jefferies Upgrades Regeneron Pharmaceuticals to Hold, Raises Price Target to $675
REGNSeptember 9, 2022
Read more →Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease
REGNSeptember 8, 2022
Read more →Regeneron Highlights Dupixent (dupilumab) Late-Breaking Phase 3 Data At The EADV 2022 Congress; Says Data Show Significant Improvements In Signs And Symptoms Of Prurigo Nodularis
REGNSeptember 8, 2022
Read more →Regeneron Pharmaceuticals Shares Resume Trade Following Circuit Breaker Halt, Stock Now Up 13.9%
REGNSeptember 8, 2022
Read more →Regeneron Says Aflibercept 8mg Meets Primary Endpoints In 2 Global Pivotal Trials For DME And wAMD, With Vast Majority Of Patients Maintained On 12- And 16-Week Dosing Intervals
REGNSeptember 8, 2022
Read more →Regeneron Pharmaceuticals Shares Halted, News Pending
REGNSeptember 8, 2022
Read more →$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much
REGNRegeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.55% on an annualized basis producing an average annual return of 19.7%. Currently, Regeneron Pharmaceuticals has a market capitalization of $72.59 billion.
May 4, 2022
Read more →Regeneron Posts Drop In Q1 Profit As COVID Antibody Sales Hit, Shares Fall
REGNMay 4, 2022
Read more →Regeneron Pharmaceuticals: Q1 Earnings Insights
REGNRegeneron Pharmaceuticals (NASDAQ:REGN) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
May 4, 2022
Read more →Regeneron Raises FY22 R&D Guidance From $2.8B-$3B To $2.9B-$3.1B
REGNMay 4, 2022
Read more →Regeneron Pharmaceuticals Q1 Adj. EPS $11.49 Beats $10.04 Estimate, Sales $2.97B Beat $2.73B Estimate
REGNMay 4, 2022
Read more →Where Regeneron Pharmaceuticals Stands With Analysts
REGNAnalysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:
May 2, 2022
Read more →Here's Why This Analyst Cut Price Target On Regeneron
REGNMay 2, 2022
Read more →RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Lowers Price Target to $647
REGNMay 2, 2022
Read more →